DTIL NASDAQ
Precision BioSciences, Inc.
1W: +1.4%
1M: -15.3%
3M: -23.4%
YTD: +53.9%
1Y: +16.0%
3Y: -43.1%
5Y: -98.3%
$6.31
-0.02 (-0.32%)
Weekly Expected Move ±8.7%
$5
$6
$6
$7
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships7
As Filer
counterparties named
1
As Counterparty
mentioned by others
1
Rel. Types
2022-06-21
Earliest Filing
2024-08-06
Latest Filing
partner: 7
Counterparties (Filed by DTIL)
7 relationshipsCompanies named in DTIL's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | TGTX | partner | Partnered with Precision BioSciences for an exclusive license to develop azer-cel for autoimmune diseases. | 2024-01-11 | View |
| TG Cell Therapy, Inc. | — | partner | Subsidiary of TG Therapeutics that entered into the License Agreement with Precision BioSciences. | 2024-01-11 | View |
| Venable Historic, LLC | — | partner | Landlord entering into a Tenth Amendment to Lease Agreement for office and lab space | 2023-10-19 | View |
| Venable Tenant, LLC | — | partner | Original tenant whose lease agreement is being amended | 2023-10-19 | View |
| Prevail Therapeutics Inc. | — | partner | Wholly owned subsidiary of Eli Lilly and Company that entered into an amended and restated development and license agree | 2023-07-06 | View |
| Eli Lilly and Company | LLY | partner | Parent company of Prevail Therapeutics Inc. that previously held the original development and license agreement with Pre | 2023-07-06 | View |
| Novartis Pharma AG | NVSEF | partner | Entered into a collaboration and license agreement and stock purchase agreement with Precision BioSciences, Inc. to deve | 2022-06-21 | View |
Mentioned As Counterparty
1 mentionsOther companies that named DTIL in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-24 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-27 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-07-01 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-16 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-05-27 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-26 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-03-17 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-11 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-11-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-02 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-03 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-15 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR